Moreover, in patient-derived xenograft models, CLTX-CAR T cells effectively targeted tumors even with low expression levels of other GBM-associated antigens, such as IL13Rα2, HER2, or EGFR. This evidence concerns the gene ERBB2 and glioblastoma.